Carl McDonald

In a report published Thursday, Citigroup analyst Carl McDonald downgraded Humana (NYSE: HUM) from Buy to Neutral, but raised the price target from $87.00 to $95.00. In the report, Citigroup noted, “We think there's upside to Humana's 2013 guidance, but so does everyone else. For 2014, the view...

In a report published Wednesday, Citigroup analyst Carl McDonald reiterated a Buy rating on Aetna (NYSE: AET), and raised the price target from $68.00 to $72.00. In the report, Citigroup noted, “Aetna is one of the only large-cap companies in the group already willing to commit to earnings...

After the announcement last month that Cigna (NYSE: CI) would acquire HealthSpring (NYSE: HS) in a $3.8 billion deal, both companies announced on Monday that they had overcome regulatory hurdles to their union. The deal—still subject to shareholder approval that is expected by the first half of...

Shares of Triple-S Management Corp (NYSE: GTS) dropped 15% today after it announced it lost its Medicaid business. Citi analysts seem unfazed, and did not change its price target of $25.00. Citi analysts said, "The bad news is that the Medicaid business accounts for 20% of the company’s health care...

Analysts Carl McDonald and James Nakllckl at Oppenheimer have released an update on Magellan Health Services, Inc. (NASDAQ: MGLN). Last week, the company reported its first-quarter results. Magellan Health Services reported first-quarter EPS of $0.73. According to analysts, for the company to show...